Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel therapeutic candidates that regulate cellular growth and repair,
announced that a late breaking abstract describing results from the
ACE-083 Phase 1 clinical trial has been selected for an oral plenary
presentation in the Late Breaking Clinical Trials Session at the 8th
International Conference on Cachexia, Sarcopenia, and Muscle
Wasting. The conference will take place in Paris, France, December 4-6,
2015.

ACE-083 has been designed to increase muscle mass and strength
selectively in the muscles into which the drug is
administered. Acceleron is developing ACE-083 for diseases such as
facioscapulohumeral and certain other forms of muscular dystrophy in
which improved muscle strength in a specific set of muscles may provide
a clinical benefit.

 

Oral Presentation

Date:   Saturday, December 5
Title:

A Phase 1 Dose Escalation Study of ACE-083 in Healthy
Volunteers: Preliminary Results for a Locally Acting Muscle
Therapeutic
(Abstract #1-72)

Session: 55. Clinical science track: Late breaking clinical trials & trial
updates
Time: 4:30 – 6:30 PM CET
Location: Novotel Paris Tour Eiffel, Hall A
 

Poster Presentation

Date: Sunday, December 6
Title:

A Phase 1 Dose Escalation Study of ACE-083 in Healthy
Volunteers: Preliminary Results for a Locally Acting Muscle
Therapeutic
(Abstract #1-72)

Session: 16. Muscle wasting, sarcopenia, myopenia VI
Time: 9:35 – 10:25 AM CET
Location: Novotel Paris Tour Eiffel, Poster Area
 

The clinical presentation and poster will be available on Acceleron’s
website (www.acceleronpharma.com)
under the “Publications” tab when presented at the conference.

About ACE-083

ACE-083 is a therapeutic candidate that acts as a ligand trap for
members in the Transforming Growth Factor-Beta (TGF-β) superfamily
involved in the regulation of muscle mass and strength. ACE-083 has been
designed to increase muscle mass and strength selectively in the muscles
into which the drug is administered. Acceleron is developing ACE-083 for
diseases in which improved muscle strength in a specific set of muscles
may provide a clinical benefit, such as facioscapulohumeral and certain
other forms of muscular dystrophy. ACE-083 is currently in a phase 1
clinical trial in healthy volunteers. For additional information on this
clinical trial, please visit www.clinicaltrials.gov,
identifier NCT02257489.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the
discovery, development and commercialization of novel therapeutic
candidates that regulate cellular growth and repair. The company is a
leader in understanding the biology of the Transforming Growth
Factor-Beta (TGF-β) protein superfamily, a large and diverse group of
molecules that are key regulators in the growth and repair of tissues
throughout the human body, and in targeting these pathways to develop
important new medicines. Acceleron has built a highly productive R&D
platform that has generated innovative clinical and preclinical
therapeutic candidates with novel mechanisms of action. These
therapeutic candidates have the potential to significantly improve
clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

Contacts

Acceleron Pharma Inc.
Todd James, 617-649-9393
Senior
Director, Corporate Communications
or
Media:
BMC
Communications LLC
Brad Miles, 646-513-3125